journal
https://read.qxmd.com/read/38471458/improved-detection-of-colibactin-induced-mutations-by-genotoxic-e-%C3%A2-coli-in-organoids-and-colorectal-cancer
#21
JOURNAL ARTICLE
Axel Rosendahl Huber, Cayetano Pleguezuelos-Manzano, Jens Puschhof, Joske Ubels, Charelle Boot, Aurelia Saftien, Mark Verheul, Laurianne T Trabut, Niels Groenen, Markus van Roosmalen, Kyanna S Ouyang, Henry Wood, Phil Quirke, Gerrit Meijer, Edwin Cuppen, Hans Clevers, Ruben van Boxtel
Co-culture of intestinal organoids with a colibactin-producing pks+ E. coli strain (EcC) revealed mutational signatures also found in colorectal cancer (CRC). E. coli Nissle 1917 (EcN) remains a commonly used probiotic, despite harboring the pks operon and inducing double strand DNA breaks. We determine the mutagenicity of EcN and three CRC-derived pks+ E. coli strains with an analytical framework based on sequence characteristic of colibactin-induced mutations. All strains, including EcN, display varying levels of mutagenic activity...
March 11, 2024: Cancer Cell
https://read.qxmd.com/read/38471457/exploiting-the-therapeutic-implications-of-kras-inhibition-on-tumor-immunity
#22
REVIEW
Miriam Molina-Arcas, Julian Downward
Over the past decade, RAS oncogenic proteins have transitioned from being deemed undruggable to having two clinically approved drugs, with several more in advanced stages of development. Despite the initial benefit of KRAS-G12C inhibitors for patients with tumors harboring this mutation, the rapid emergence of drug resistance underscores the urgent need to synergize these inhibitors with other therapeutic approaches to improve outcomes. RAS mutant tumor cells can create an immunosuppressive tumor microenvironment (TME), suggesting an increased susceptibility to immunotherapies following RAS inhibition...
March 11, 2024: Cancer Cell
https://read.qxmd.com/read/38471456/stress-induced-metastasis-the-net-effect
#23
JOURNAL ARTICLE
Jing Hu
Chronic stress correlates with cancer progression and metastasis, yet the underlying mechanisms remain to be explored. In this issue of Cancer Cell, He et al. reveal that glucocorticoids released during chronic stress promote metastasis by inducing the formation of neutrophil extracellular traps (NETs) and remodeling the microenvironment.
March 11, 2024: Cancer Cell
https://read.qxmd.com/read/38471455/insights-into-how-adeno-squamous-transition-drives-kras-inhibitor-resistance
#24
JOURNAL ARTICLE
Feng Hu, Piro Lito
The histologic transformation of adenocarcinoma (ADC) to squamous cell carcinoma (SCC), known as adeno-squamous transition or AST, is frequently observed in patients with lung cancer undergoing cancer therapy. In this issue, Tong and colleagues investigate genetic and epigenetic mechanisms that drive AST to confer resistance to KRAS inhibitors in preclinical models and patients.
March 11, 2024: Cancer Cell
https://read.qxmd.com/read/38366590/vascular-characterization-reveals-immunomodulatory-targets-for-brain-metastases
#25
JOURNAL ARTICLE
Roberta Lugano, Anna Dimberg
Brain metastases are clinically challenging due to the unique brain microenvironment. In this issue of Cancer Cell, Bejarano et al. use transcriptional profiling and data integration to shed light on the molecular and cellular composition of the vasculature in brain metastases, identifying CD276 as an immunomodulatory target for therapy.
March 11, 2024: Cancer Cell
https://read.qxmd.com/read/38366589/immune-heterogeneity-in-small-cell-lung-cancer-and-vulnerability-to-immune-checkpoint-blockade
#26
JOURNAL ARTICLE
Barzin Y Nabet, Habib Hamidi, Myung Chang Lee, Romain Banchereau, Stefanie Morris, Leah Adler, Velimir Gayevskiy, Ahmed M Elhossiny, Minu K Srivastava, Namrata S Patil, Kiandra A Smith, Rajiv Jesudason, Caleb Chan, Patrick S Chang, Matthew Fernandez, Sandra Rost, Lisa M McGinnis, Hartmut Koeppen, Carl M Gay, John D Minna, John V Heymach, Joseph M Chan, Charles M Rudin, Lauren A Byers, Stephen V Liu, Martin Reck, David S Shames
Atezolizumab (anti-PD-L1), combined with carboplatin and etoposide (CE), is now a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A clearer understanding of therapeutically relevant SCLC subsets could identify rational combination strategies and improve outcomes. We conduct transcriptomic analyses and non-negative matrix factorization on 271 pre-treatment patient tumor samples from IMpower133 and identify four subsets with general concordance to previously reported SCLC subtypes (SCLC-A, -N, -P, and -I)...
March 11, 2024: Cancer Cell
https://read.qxmd.com/read/38215747/integrated-proteogenomic-characterization-of-glioblastoma-evolution
#27
JOURNAL ARTICLE
Kyung-Hee Kim, Simona Migliozzi, Harim Koo, Jun-Hee Hong, Seung Min Park, Sooheon Kim, Hyung Joon Kwon, Seokjun Ha, Luciano Garofano, Young Taek Oh, Fulvio D'Angelo, Chan Il Kim, Seongsoo Kim, Ji Yoon Lee, Jiwon Kim, Jisoo Hong, Eun-Hae Jang, Bertrand Mathon, Anna-Luisa Di Stefano, Franck Bielle, Alice Laurenge, Alexey I Nesvizhskii, Eun-Mi Hur, Jinlong Yin, Bingyang Shi, Youngwook Kim, Kyung-Sub Moon, Jeong Taik Kwon, Shin Heon Lee, Seung Hoon Lee, Ho Shin Gwak, Anna Lasorella, Heon Yoo, Marc Sanson, Jason K Sa, Chul-Kee Park, Do-Hyun Nam, Antonio Iavarone, Jong Bae Park
The evolutionary trajectory of glioblastoma (GBM) is a multifaceted biological process that extends beyond genetic alterations alone. Here, we perform an integrative proteogenomic analysis of 123 longitudinal glioblastoma pairs and identify a highly proliferative cellular state at diagnosis and replacement by activation of neuronal transition and synaptogenic pathways in recurrent tumors. Proteomic and phosphoproteomic analyses reveal that the molecular transition to neuronal state at recurrence is marked by post-translational activation of the wingless-related integration site (WNT)/ planar cell polarity (PCP) signaling pathway and BRAF protein kinase...
March 11, 2024: Cancer Cell
https://read.qxmd.com/read/38350424/benchmarking-mismatch-repair-testing-for-patients-with-cancer-receiving-immunotherapy
#28
Elias Bou Farhat, Elio Adib, Melissa Daou, Abdul Rafeh Naqash, Ursula Matulonis, Kimmie Ng, David J Kwiatkowski, Lynette M Sholl, Amin H Nassar
No abstract text is available yet for this article.
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38350423/the-intratumor-mycobiome-promotes-lung-cancer-progression-via-myeloid-derived-suppressor-cells
#29
Ning-Ning Liu, Cheng-Xiang Yi, Lu-Qi Wei, Jin-An Zhou, Tong Jiang, Cong-Cong Hu, Lu Wang, Yuan-Yuan Wang, Yun Zou, Yi-Kai Zhao, Le-Le Zhang, Ya-Ting Nie, Yi-Jing Zhu, Xin-Yao Yi, Ling-Bing Zeng, Jing-Quan Li, Xiao-Tian Huang, Hong-Bin Ji, Zisis Kozlakidis, Lin Zhong, Christopher Heeschen, Xiao-Qi Zheng, Changbin Chen, Peng Zhang, Hui Wang
No abstract text is available yet for this article.
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38350422/actomyosin-mediated-cellular-tension-drives-increased-tissue-stiffness-and-%C3%AE-catenin-activation-to-induce-epidermal-hyperplasia-and-tumor-growth
#30
Michael S Samuel, Jose I Lopez, Ewan J McGhee, Daniel R Croft, David Strachan, Paul Timpson, June Munro, Ewald Schröder, Jing Zhou, Valerie G Brunton, Nick Barker, Hans Clevers, Owen J Sansom, Kurt I Anderson, Valerie M Weaver, Michael F Olson
No abstract text is available yet for this article.
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38350421/precision-treatment-in-advanced-hepatocellular-carcinoma
#31
REVIEW
Xupeng Yang, Chen Yang, Shu Zhang, Haigang Geng, Andrew X Zhu, René Bernards, Wenxin Qin, Jia Fan, Cun Wang, Qiang Gao
The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies have not achieved universal success and HCC patients frequently exhibit therapeutic resistance to these therapies. Precision treatment represents a paradigm shift in cancer treatment in recent years. This approach utilizes the unique molecular characteristics of individual patient to personalize treatment modalities, aiming to maximize therapeutic efficacy while minimizing side effects...
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38350420/envision-the-future-of-precision-medicine-in-pediatric-cancer
#32
COMMENT
Y A DeClerck
Exploring the diversity within the tumor microenvironment (TME) can offer crucial insights to steer cancer therapy toward precision medicine. In this issue of Cancer Cell, Wienke et al. undertake a comprehensive single-cell analysis of neuroblastoma, unveiling its immune landscape and identifying NECTIN2-TIGIT as a promising target for immunotherapy.
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38350419/re-inventing-a-better-wheel-serplulimab-for-squamous-cell-lung-cancer
#33
COMMENT
Derek De-Rui Huang, James Chih-Hsin Yang
Immune checkpoint inhibitors have reshaped the treatment landscape of non-small cell lung cancer (NSCLC). However, chemoimmunotherapy trials dedicated to squamous NSCLC are limited. In this issue of Cancer Cell, Zhou et al. demonstrate serplulimab plus chemotherapy as an effective first-line regimen to treat patients with advanced squamous NSCLC.
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38278150/inosine-induces-stemness-features-in-car-t-cells-and-enhances-potency
#34
JOURNAL ARTICLE
Dorota D Klysz, Carley Fowler, Meena Malipatlolla, Lucille Stuani, Katherine A Freitas, Yiyun Chen, Stefanie Meier, Bence Daniel, Katalin Sandor, Peng Xu, Jing Huang, Louai Labanieh, Vimal Keerthi, Amaury Leruste, Malek Bashti, Janette Mata-Alcazar, Nikolaos Gkitsas, Justin A Guerrero, Chris Fisher, Sunny Patel, Kyle Asano, Shabnum Patel, Kara L Davis, Ansuman T Satpathy, Steven A Feldman, Elena Sotillo, Crystal L Mackall
Adenosine (Ado) mediates immune suppression in the tumor microenvironment and exhausted CD8+ CAR-T cells express CD39 and CD73, which mediate proximal steps in Ado generation. Here, we sought to enhance CAR-T cell potency by knocking out CD39, CD73, or adenosine receptor 2a (A2aR) but observed only modest effects. In contrast, overexpression of Ado deaminase (ADA-OE), which metabolizes Ado to inosine (INO), induced stemness and enhanced CAR-T functionality. Similarly, CAR-T cell exposure to INO augmented function and induced features of stemness...
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38278149/tumor-and-circulating-free-dna-methylation-identifies-clinically-relevant-small-cell-lung-cancer-subtypes
#35
JOURNAL ARTICLE
Simon Heeke, Carl M Gay, Marcos R Estecio, Hai Tran, Benjamin B Morris, Bingnan Zhang, Ximing Tang, Maria Gabriela Raso, Pedro Rocha, Siqi Lai, Edurne Arriola, Paul Hofman, Veronique Hofman, Prasad Kopparapu, Christine M Lovly, Kyle Concannon, Luana Guimaraes De Sousa, Whitney Elisabeth Lewis, Kimie Kondo, Xin Hu, Azusa Tanimoto, Natalie I Vokes, Monique B Nilsson, Allison Stewart, Maarten Jansen, Ildikó Horváth, Mina Gaga, Vasileios Panagoulias, Yael Raviv, Danny Frumkin, Adam Wasserstrom, Aharona Shuali, Catherine A Schnabel, Yuanxin Xi, Lixia Diao, Qi Wang, Jianjun Zhang, Peter Van Loo, Jing Wang, Ignacio I Wistuba, Lauren A Byers, John V Heymach
Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained challenging, particularly due to limited tissue availability. Given the known epigenetic regulation of critical SCLC transcriptional programs, we hypothesized that subtype-specific patterns of DNA methylation could be detected in tumor or blood from SCLC patients. Using genomic-wide reduced-representation bisulfite sequencing (RRBS) in two cohorts totaling 179 SCLC patients and using machine learning approaches, we report a highly accurate DNA methylation-based classifier (SCLC-DMC) that can distinguish SCLC subtypes...
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38278148/unlocking-car-t%C3%A2-cell-potential-inosine-induced-stemness-and-enhanced-potency
#36
COMMENT
Xingying Zhang, Haoyi Wang
Adenosine (Ado) drives immune suppression in the tumor microenvironment. In this issue of Cancer Cell, Klysz et al. investigate Ado-mediated immunosuppression. Overexpression of Ado deaminase (ADA-OE), metabolizing Ado to inosine (INO), induces stemness and improves CAR T cell functionality. Likewise, exposure to INO enhances CAR T cells' function and induces stemness features.
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38215750/a-comprehensive-clinically-informed-map-of-dependencies-in-cancer-cells-and-framework-for-target-prioritization
#37
JOURNAL ARTICLE
Clare Pacini, Emma Duncan, Emanuel Gonçalves, James Gilbert, Shriram Bhosle, Stuart Horswell, Emre Karakoc, Howard Lightfoot, Ed Curry, Francesc Muyas, Monsif Bouaboula, Chandra Sekhar Pedamallu, Isidro Cortes-Ciriano, Fiona M Behan, Lykourgos-Panagiotis Zalmas, Andrew Barthorpe, Hayley Francies, Steve Rowley, Jack Pollard, Pedro Beltrao, Leopold Parts, Francesco Iorio, Mathew J Garnett
Genetic screens in cancer cell lines inform gene function and drug discovery. More comprehensive screen datasets with multi-omics data are needed to enhance opportunities to functionally map genetic vulnerabilities. Here, we construct a second-generation map of cancer dependencies by annotating 930 cancer cell lines with multi-omic data and analyze relationships between molecular markers and cancer dependencies derived from CRISPR-Cas9 screens. We identify dependency-associated gene expression markers beyond driver genes, and observe many gene addiction relationships driven by gain of function rather than synthetic lethal effects...
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38215749/response-to-bruton-s-tyrosine-kinase-inhibitors-in-aggressive-lymphomas-linked-to-chronic-selective-autophagy
#38
JOURNAL ARTICLE
James D Phelan, Sebastian Scheich, Jaewoo Choi, George W Wright, Björn Häupl, Ryan M Young, Sara A Rieke, Martine Pape, Yanlong Ji, Henning Urlaub, Arnold Bolomsky, Carmen Doebele, Alena Zindel, Tanja Wotapek, Monica Kasbekar, Brett Collinge, Da Wei Huang, Zana A Coulibaly, Vivian M Morris, Xiaoxuan Zhuang, Julius C Enssle, Xin Yu, Weihong Xu, Yandan Yang, Hong Zhao, Zhuo Wang, Andy D Tran, Christopher J Shoemaker, Galina Shevchenko, Daniel J Hodson, Arthur L Shaffer, Louis M Staudt, Thomas Oellerich
Diffuse large B cell lymphoma (DLBCL) is an aggressive, profoundly heterogeneous cancer, presenting a challenge for precision medicine. Bruton's tyrosine kinase (BTK) inhibitors block B cell receptor (BCR) signaling and are particularly effective in certain molecular subtypes of DLBCL that rely on chronic active BCR signaling to promote oncogenic NF-κB. The MCD genetic subtype, which often acquires mutations in the BCR subunit, CD79B, and in the innate immune adapter, MYD88L265P , typically resists chemotherapy but responds exceptionally to BTK inhibitors...
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38215748/clinical-and-molecular-features-of-acquired-resistance-to-immunotherapy-in-non-small-cell-lung-cancer
#39
JOURNAL ARTICLE
Danish Memon, Adam J Schoenfeld, Darwin Ye, George Fromm, Hira Rizvi, Xiang Zhang, Mohamed Reda Keddar, Divij Mathew, Kyung Jin Yoo, Jingya Qiu, Jayon Lihm, Jayalaksmi Miriyala, Jennifer L Sauter, Jia Luo, Andrew Chow, Umesh K Bhanot, Caroline McCarthy, Chad M Vanderbilt, Cailian Liu, Mohsen Abu-Akeel, Andrew J Plodkowski, Nicholas McGranahan, Marta Łuksza, Benjamin D Greenbaum, Taha Merghoub, Ikbel Achour, J Carl Barrett, Ross Stewart, Pedro Beltrao, Taylor H Schreiber, Andy J Minn, Martin L Miller, Matthew D Hellmann
Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFNγ response genes. Upregulation of IFNγ response genes is associated with putative routes of resistance characterized by signatures of persistent IFN signaling, immune dysfunction, and mutations in antigen presentation genes which can be recapitulated in multiple murine models of acquired resistance to PD-(L)1 blockade after in vitro IFNγ treatment...
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38181798/interferon-stimulated-neutrophils-as-a-predictor-of-immunotherapy-response
#40
JOURNAL ARTICLE
Madeleine Benguigui, Tim J Cooper, Prajakta Kalkar, Sagie Schif-Zuck, Ruth Halaban, Antonella Bacchiocchi, Iris Kamer, Abhilash Deo, Bar Manobla, Rotem Menachem, Jozafina Haj-Shomaly, Avital Vorontsova, Ziv Raviv, Chen Buxbaum, Petros Christopoulos, Jair Bar, Michal Lotem, Mario Sznol, Amiram Ariel, Shai S Shen-Orr, Yuval Shaked
Despite the remarkable success of anti-cancer immunotherapy, its effectiveness remains confined to a subset of patients-emphasizing the importance of predictive biomarkers in clinical decision-making and further mechanistic understanding of treatment response. Current biomarkers, however, lack the power required to accurately stratify patients. Here, we identify interferon-stimulated, Ly6Ehi neutrophils as a blood-borne biomarker of anti-PD1 response in mice at baseline. Ly6Ehi neutrophils are induced by tumor-intrinsic activation of the STING (stimulator of interferon genes) signaling pathway and possess the ability to directly sensitize otherwise non-responsive tumors to anti-PD1 therapy, in part through IL12b-dependent activation of cytotoxic T cells...
February 12, 2024: Cancer Cell
journal
journal
39886
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.